MSCT helps I-ELCAP spot latent lung cancers

Article

Tiny solid lung cancers in asymptomatic patients are less likely than larger ones to have metastasized. These early tumors with no metastases have a good curability rate, according to research from the International Early Lung Cancer Action Program.

Tiny solid lung cancers in asymptomatic patients are less likely than larger ones to have metastasized. These early tumors with no metastases have a good curability rate, according to research from the International Early Lung Cancer Action Program.

I-ELCAP screening data from nearly 29,000 patients yielded 464 cancers. Of these, 436 were non-small cell carcinomas, which are less aggressive than small cell cancer. Researchers found 85% of the NSC group had no metastases (Arch Intern Med 2006;166:321-325).

Size was directly related to metastatic rate: 91% of tumors 15 mm or smaller had no metastases, while 55% of tumors 36 mm or larger had no metastases. Solid lesions had a stronger correlation between size and metastases than part-solid lesions, while no association existed for nonsolid lesions.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.